Clobazam
Onfi, SYMPAZAN
Benzodiazepine
NADAC/unit
$0.1552
No Shortage
Tier 1: 114.0%
PA Req: 424.3%
14 Manufacturers
28 ANDAs
Clobazam treats anxiety, seizures, and insomnia by enhancing GABA activity in the brain.
vs. brand Onfi: Generic saves up to 98% per unit
Market Intelligence
2025-01-22 Class II Recall: Amerisource Health Services LLC
2025-01-15 Class II Recall: Amerisource Health Services LLC
2024-02-28 Class II Recall: Micro Labs Limited
Generic Manufacturers
ALKEM LABORATORIES LTDAMNEAL PHARMACEUTICALS CO GMBHAMNEAL PHARMACEUTICALS LLCASSERTIO SPECIALTY PHARMACEUTICALS LLCAUROBINDO PHARMA LTDBIONPHARMA INCCHARTWELL MOLECULAR HOLDINGS LLCHETERO LABS LTD UNIT IIILUNDBECK PHARMACEUTICALS LLCLUPIN LTDMICRO LABS LTDMSN LABORATORIES PRIVATE LTDPIRAMAL HEALTHCARE UK LTDTARO PHARMACEUTICAL INDUSTRIES LTDUPSHER SMITH LABORATORIES LLCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.